Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.

Ojemuyiwa M, Zeman K, Spira A, Oronsky B, Ray C, Trepel JB, Lee MJ, Onyiuke I, Brzezniak C.

Clin Case Rep. 2018 Nov 5;6(12):2478-2481. doi: 10.1002/ccr3.1880. eCollection 2018 Dec.

2.

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs).

Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter CA, Reid TR.

Oncoimmunology. 2018 Jul 23;7(9):e1478648. doi: 10.1080/2162402X.2018.1478648. eCollection 2018. Review.

PMID:
30228948
3.

Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer.

Oronsky B, Larson C, Reid TR, Carter CA.

J Investig Med High Impact Case Rep. 2018 Jul 6;6:2324709618786319. doi: 10.1177/2324709618786319. eCollection 2018 Jan-Dec.

4.

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.

Oronsky B, Oronsky N, Cabrales P.

J Cell Mol Med. 2018 Oct;22(10):5076-5082. doi: 10.1111/jcmm.13791. Epub 2018 Jul 16.

5.

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

Oronsky B, Reid TR, Oronsky A, Caroen S, Carter CA, Cabrales P.

Oncotarget. 2018 May 4;9(34):23439-23442. doi: 10.18632/oncotarget.25211. eCollection 2018 May 4.

6.

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

Oronsky B, Goyal S, Kim MM, Cabrales P, Lybeck M, Caroen S, Oronsky N, Burbano E, Carter C, Oronsky A.

Transl Oncol. 2018 Jun;11(3):771-778. doi: 10.1016/j.tranon.2018.03.014. Epub 2018 Apr 23. Review.

7.

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet.

Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E.

J Investig Med High Impact Case Rep. 2018 Mar 7;6:2324709618760080. doi: 10.1177/2324709618760080. eCollection 2018 Jan-Dec.

8.

A note on improved statistical approaches to account for pseudoprogression.

Abrouk N, Oronsky B, Caroen S, Ning S, Knox S, Peehl D.

Cancer Chemother Pharmacol. 2018 Mar;81(3):621-626. doi: 10.1007/s00280-018-3529-4. Epub 2018 Feb 5.

PMID:
29404682
9.

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.

Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL.

Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24.

10.

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.

Oronsky B, Ma P, Reid TR, Cabrales P, Lybeck M, Oronsky A, Oronsky N, Carter CA.

Neoplasia. 2018 Jan;20(1):92-98. doi: 10.1016/j.neo.2017.11.001. Epub 2017 Dec 8. Review.

11.

No patient left behind: The promise of immune priming with epigenetic agents.

Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR.

Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017. Review.

12.

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Oronsky B, Ma PC, Morgensztern D, Carter CA.

Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5. Review.

13.

A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.

Brzezniak C, Oronsky B, Aggarwal R.

Eur Urol. 2018 Feb;73(2):306-307. doi: 10.1016/j.eururo.2017.09.010. Epub 2017 Sep 21. No abstract available.

PMID:
28943185
14.

What's New in SCLC? A Review.

Oronsky B, Reid TR, Oronsky A, Carter CA.

Neoplasia. 2017 Oct;19(10):842-847. doi: 10.1016/j.neo.2017.07.007. Epub 2017 Sep 6. Review.

15.

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.

Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, Reid TR, Carter CA.

Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20. Review.

16.

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report.

Brzezniak C, Oronsky B, Carter CA, Thilagar B, Caroen S, Zeman K.

Case Rep Oncol. 2017 Mar 17;10(1):252-257. doi: 10.1159/000464278. eCollection 2017 Jan-Apr.

17.

Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report.

Oronsky N, Thilagar B, Ray CM, Caroen S, Lybeck MMC, Ferry L, Voves RA, Oronsky B.

Case Rep Oncol. 2017 Apr 6;10(1):325-327. doi: 10.1159/000470833. eCollection 2017 Jan-Apr.

18.

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome.

Brzezniak CE, Vietor N, Hogan PE, Oronsky B, Thilagar B, Ray CM, Caroen S, Lybeck M, Oronsky N, Carter CA.

Case Rep Oncol. 2017 Apr 6;10(1):321-324. doi: 10.1159/000467390. eCollection 2017 Jan-Apr.

19.

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

Brzezniak C, Oronsky B, Trepel J, Summers TA Jr, Cabrales P, Lee MJ, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck HE, Brown JF, Reid TR, Carter CA.

Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr.

20.

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.

Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B.

Expert Rev Hematol. 2017 Jun;10(6):575-582. doi: 10.1080/17474086.2017.1324779. Epub 2017 May 22.

PMID:
28448172
21.

A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.

Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM.

Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25. Review.

PMID:
28444622
22.

RRx-001 protects against cisplatin-induced toxicities.

Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, Oronsky A, Cabrales P.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1671-1677. doi: 10.1007/s00432-017-2416-4. Epub 2017 Apr 17.

PMID:
28417195
23.

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.

Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.

24.

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.

Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA.

Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Review. Erratum in: Expert Opin Investig Drugs. 2017 Feb;26(2):261. Carterg, Corey A [corrected to Carter, Corey A].

25.

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA.

Oncol Res Treat. 2016;39(11):720-723. Epub 2016 Sep 19.

PMID:
27855386
26.

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA.

Clin Med Insights Oncol. 2016 Nov 6;10:105-108. eCollection 2016.

27.

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.

Das DS, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC.

Leukemia. 2016 Nov;30(11):2187-2197. doi: 10.1038/leu.2016.96. Epub 2016 Apr 27.

28.

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.

Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B.

Oncotarget. 2016 Jun 28;7(26):40781-40791. doi: 10.18632/oncotarget.8205. Review.

29.

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C.

Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.

30.

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents.

Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A.

Biomolecules. 2016 Jul 4;6(3). pii: E32. doi: 10.3390/biom6030032. Review.

31.

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

Fens MH, Cabrales P, Scicinski J, Larkin SK, Suh JH, Kuypers FA, Oronsky N, Lybeck M, Oronsky A, Oronsky B.

Med Oncol. 2016 Aug;33(8):85. doi: 10.1007/s12032-016-0798-9. Epub 2016 Jul 4.

PMID:
27377482
32.

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C.

Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. eCollection 2016.

33.

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

Carter CA, Scicinski JJ, Lybeck HE, Oronsky BT.

Case Rep Oncol. 2016 Apr 23;9(1):246-8. doi: 10.1159/000446064. eCollection 2016 Jan-Apr.

34.

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.

Oronsky B, Scicinski J, Reid T, Oronsky A, Carter C, Oronsky N, Cabrales P.

Discov Med. 2016 Apr;21(116):251-65.

35.

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B.

Med Oncol. 2016 Jul;33(7):63. doi: 10.1007/s12032-016-0775-3. Epub 2016 May 26.

PMID:
27229330
36.

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.

Oronsky B, Scicinski J, Cabrales P, Minchinton A.

Clin Epigenetics. 2016 May 11;8:53. doi: 10.1186/s13148-016-0220-7. eCollection 2016.

37.

"No patient left behind": an alternative to "the War on Cancer" metaphor.

Oronsky BT, Carter CA, Oronsky AL, Salacz ME, Reid T.

Med Oncol. 2016 Jun;33(6):55. doi: 10.1007/s12032-016-0769-1. Epub 2016 Apr 29.

PMID:
27129923
38.

Rockets, radiosensitizers, and RRx-001: an origin story part I.

Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.

Discov Med. 2016 Mar;21(115):173-80. Review.

39.

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.

Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Transl Oncol. 2016 Apr;9(2):108-113. doi: 10.1016/j.tranon.2015.12.003.

40.

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C.

Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.

41.

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C.

Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016 Jan-Apr.

42.

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis.

Carter CA, Browning R, Oronsky BT, Scicinski JJ, Brzezniak C.

Case Rep Oncol. 2016 Jan 27;9(1):68-75. doi: 10.1159/000443723. eCollection 2016 Jan-Apr.

43.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C.

Case Rep Oncol. 2016 Jan 28;9(1):62-7. doi: 10.1159/000443725. eCollection 2016 Jan-Apr.

44.

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA.

Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016 Jan-Apr.

45.

RRx-001, A novel dinitroazetidine radiosensitizer.

Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S.

Invest New Drugs. 2016 Jun;34(3):371-7. doi: 10.1007/s10637-016-0326-y. Epub 2016 Feb 3. Review.

46.

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy.

Oronsky B, Carter C, Scicinska A, Oronsky A, Oronsky N, Lybeck M, Scicinski J.

Oncotarget. 2016 Feb 23;7(8):9041-5. doi: 10.18632/oncotarget.6984.

47.

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.

Kim MM, Parmar H, Cao Y, Knox SJ, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Neuro Oncol. 2016 Mar;18(3):455-6. doi: 10.1093/neuonc/nov317. Epub 2016 Jan 13. No abstract available.

48.

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.

Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Oncotarget. 2015 Dec 22;6(41):43172-81. doi: 10.18632/oncotarget.6526.

49.

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.

Carter CA, Degesys A, Oronsky B, Scicinski J, Caroen SZ, Oronsky AL, Reid T, Cabrales P, Roswarski J.

Case Rep Oncol. 2015 Oct 30;8(3):461-5. doi: 10.1159/000441775. eCollection 2015 Sep-Dec.

50.

Dysphonia after Bevacizumab Rechallenge: A Case Report.

Carter CA, Caroen SZ, Oronsky AL, Oronsky BT.

Case Rep Oncol. 2015 Oct 14;8(3):423-5. doi: 10.1159/000441122. eCollection 2015 Sep-Dec.

Supplemental Content

Loading ...
Support Center